Compare GRRR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRRR | RGNX |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United Kingdom | United States |
| Employees | 200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.5M | 418.1M |
| IPO Year | N/A | 2015 |
| Metric | GRRR | RGNX |
|---|---|---|
| Price | $13.43 | $10.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | ★ 780.3K | 671.4K |
| Earning Date | 06-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $69.35 | $51.21 |
| Revenue Next Year | $85.38 | $19.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $9.04 | $7.35 |
| 52 Week High | $27.90 | $16.19 |
| Indicator | GRRR | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 56.32 |
| Support Level | $12.13 | $7.76 |
| Resistance Level | $15.83 | $10.65 |
| Average True Range (ATR) | 0.86 | 0.62 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 33.39 | 53.89 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.